Gritstone bio (GRTS) Scheduled to Post Earnings on Thursday

Gritstone bio (NASDAQ:GRTS - Get Free Report) will release its earnings data after the market closes on Thursday, May 9th. Analysts expect Gritstone bio to post earnings of ($0.30) per share for the quarter. Investors interested in listening to the company's conference call can do so using this link.

Gritstone bio (NASDAQ:GRTS - Get Free Report) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.10. Gritstone bio had a negative return on equity of 147.22% and a negative net margin of 847.24%. The company had revenue of $10.38 million during the quarter, compared to analysts' expectations of $4.80 million. On average, analysts expect Gritstone bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gritstone bio Price Performance

GRTS traded up $0.09 during trading on Friday, hitting $0.96. The company's stock had a trading volume of 4,188,892 shares, compared to its average volume of 2,756,496. The firm has a market capitalization of $103.13 million, a price-to-earnings ratio of -0.82 and a beta of 0.64. Gritstone bio has a twelve month low of $0.67 and a twelve month high of $3.33. The business's fifty day simple moving average is $1.75 and its 200 day simple moving average is $1.91. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.77.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Gritstone bio in a report on Wednesday, March 6th. JMP Securities boosted their target price on shares of Gritstone bio from $4.00 to $5.00 and gave the stock a "market outperform" rating in a research note on Tuesday, April 2nd.

About Gritstone bio

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.